Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
December 16, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 16, 2002
- Nippon Chemiphar: Uralyt Sales Strong but Less than Expected
December 9, 2002
- REGULATORY NEWS IN BRIEF
December 9, 2002
- Nikken Chemicals: Ethical Drug Sales Down 3.7% in 1st Half
December 9, 2002
- Kyowa Hakko to Collect Evidence on Coniel from Large Study
December 9, 2002
- Fukujin: Sales Up 14.2%, Profit Up 80.9%
December 9, 2002
- Matsumotokiyoshi: Sales Up 4.2%, Operating Profits Up 21%
December 9, 2002
- VITAL-NET: Sales Up, Operating Profits Jump
December 9, 2002
- Takeda to Start Joint Drug Discovery with Albany Molecular Research
December 9, 2002
- PhRMA Issues Program for 21st Century Health Reform in Japan
December 9, 2002
- Atol: Net Profits Down 16.3% Despite Higher Sales
December 9, 2002
- NanoCarrier, Kirin to Collaborate on Novel Anticancer Agents
December 9, 2002
- Bayer AG Actively Seeking Alliance: Mr Wenning
December 9, 2002
- Astis: Sales Up 0.9% to \44.7 Bil.
December 9, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 9, 2002
- Sankyo to Spin Off Agricultural Chemicals, Specialty Products
December 9, 2002
- Seiwa Sangyo: 4.5% Increase in Sales Boosts Profits
December 9, 2002
- Kobayashi Pharma: New Products, Cost-cutting Boost Sales and Profits
December 9, 2002
- BUSINESS NEWS IN BRIEF
December 9, 2002
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…